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Reversibility of Antipsychotic Treatment–Related Diabetes in Patients With 
Schizophrenia A case series of switching to aripiprazole  
At present, antipsychotic drugs are not specifically referred to in the list of substances that can 
induce diabetes in the most recent American Diabetes Association guidelines (1), but there is 
a growing body of evidence that antipsychotic drugs might have diabetogenic properties (2,3). 
At present, there are no clear guidelines on what the best therapeutic strategies are when 
diabetes is detected during treatment with antipsy- chotics. Data from pharmacovigilance 
studies suggest that a significant proportion of recent-onset cases of diabetes can be reversed. 
Recent Belgian guidelines for screening and monitoring patients treated with antipsychotics 
propose a switch to an antipsychotic with a safer metabolic profile, but this strategy has not 
been evaluated systematically (3). We have recently reported on five patients 
with treatment-emergent diabetes who were successfully switched to a more suitable 
antipsychotic, which resulted in the reversal of diabetes (to risperidone in one patient [4] and 
amisulpride in four patients [5]). Since aripiprazole, a second- generation antipsychotic agent 
described as having a good metabolic profile (6–8), became available on the Belgian market, 
all consecutive patients with recently detected diabetes were switched to this agent. 
Over the last year, a switch to aripiprazole was initiated in seven consecutive patients (mean 
age [_SD] 37 _ 14 years) after diabetes was detected and confirmed during their previous 
antipsychotic treatment. All patients underwent an extensive metabolic evaluation, including 
an oral glucose tolerance test (OGTT) at baseline and 6 weeks and 3 months of follow-up. 
All but two were treated with antipsychotic medication for _1 year. One patient was switched 
from a first-generation antipsychotic, one from clozapine, one from olanzapine, two from 
quetiapine, and two from risperidone. All cases of diabetes met criteria at 120 min in the 
OGTT. Two patients also met criteria for diabetes while fasting, and all others had impaired 
fasting glucose (fasting glucose between 100 and 125 mg/dl). 
All cases of recent-onset diabetes were reversed at 3 months of follow-up. Six patients had 
normal glucose values both in the fasting state and at 120 min in the OGTT. One patient had 
impaired glucose tolerance (glucose at 120 min between 140 and 200 mg/dl) at end point. 
There was a significant reduction in all glucose values in the OGTT, fasting insulin, in the 
homeostasis model assessment of insulin resistance, and in HbA1c glycated hemoglobin, 
weight, waist circumference, and BMI (online appendix [available at 
http://care.diabetesjournals.org]). 
Whether this reversibility was due to stopping the prior antipsychotic alone could not be 
evaluated. Although patients were included prospectively, the number of patients remains 
limited. The duration of the study was only 3 months, so the observed favorable evolution on 
metabolic parameters should be confirmed over a longer period of time. Future research 
should address these issues more specifically in large, multisite samples. 
To our knowledge, this is the first prospective case series addressing the metabolic safety of 
aripiprazole using an extensive metabolic evaluation in patients with recently detected 
antipsychotic treatment– emergent diabetes. If during treatment with an antipsychotic severe 
metabolic abnormalities emerge, a switch to a safer metabolic agent should be considered as 
the first treatment option if acceptable for the patient. 
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